Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price dropped 2.5% during trading on Monday . The stock traded as low as $4.79 and last traded at $4.75. Approximately 3,127 shares were traded during trading, a decline of 80% from the average daily volume of 15,404 shares. The stock had previously closed at $4.87.
Analyst Upgrades and Downgrades
Separately, Guggenheim lowered their target price on Nanobiotix from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, April 4th.
View Our Latest Analysis on NBTX
Nanobiotix Stock Up 0.3%
The company has a 50 day moving average of $4.33 and a 200 day moving average of $3.70.
Institutional Trading of Nanobiotix
Several large investors have recently added to or reduced their stakes in NBTX. Geode Capital Management LLC bought a new stake in Nanobiotix in the fourth quarter worth approximately $29,000. Millennium Management LLC bought a new stake in Nanobiotix in the fourth quarter worth $39,000. Jane Street Group LLC bought a new stake in Nanobiotix in the fourth quarter worth $73,000. Finally, OLD Mission Capital LLC bought a new stake in Nanobiotix in the fourth quarter worth $139,000. 38.81% of the stock is owned by institutional investors.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
